REPL FDA Advisory Committee: Thursday, July 30, 2026

…ed this report to be signed on its behalf by the undersigned hereunto duly authorized.     REPLIMUNE GROUP, INC.       Date: July 30, 2026 By: /s/ Sushil Patel     Sushil Patel     Chief Executive Officer       EX-99.1 2 tm2621708d1_ex99-1

Dates are sourced from official registries and filings and can change — estimated dates (marked ~) slip routinely. This page updates automatically when the source registry moves the date. Research information only, not investment advice.